Geffken Daniel E.'s Form 4 filing
Eloxx Pharmaceuticals, Inc. (ELOX) · filed Dec 1, 2021
- Accession no.
- 0001415889-21-005600
- Filed
- Dec 1, 2021
- Trade date
- Nov 29, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $36.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Geffken Daniel E.CIK 0001314756 | Officer (INTERIM CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2021 | Common Stock | PPurchaseAcquired | +50,000 | $0.72 | +$36,000 | 50,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.